Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-21
Target enrollment:
Participant gender:
Summary
This study is an open, multicenter, randomized controlled clinical trial for patients with
newly diagnosed primary invasive breast cancer and clinical stage of T2 or above. The main
purpose of this study is to evaluate the efficacy of dose-dense nab-paclitaxel compared with
dose-dense docetaxel followed by anthracycline and cyclophosphamide in the treatment of HR
positive and HER-2 negative breast cancer. The effectiveness and safety of the treatment.